CGI, Pedernera 459, X5800CGI Río Cuarto, Córdoba, Argentina
Select an option
I am a doctor
I am a sponsor
Our team
Medical staff
Ignacio Magri
Open studies
Lung cancer
Sacituzumab Tirumotecan (MK-2870) in Combination With Pembrolizumab Versus Pembrolizumab Alone in Metastatic Non-small Cell Lung Cancer (NSCLC) With Programmed Cell Death Ligand 1 (PD-L1) Tumor Proportion Score (TPS) ≥ 50% (MK-2870-007) - MK 2870-007 - Merck Sharp & Dohme LLCSee more
Sacituzumab Tirumotecan (MK-2870) Versus Pemetrexed and Carboplatin Combination Therapy in Participants With Epidermal Growth Factor (EGFR)-Mutated, Advanced Nonsquamous Non-small Cell Lung Cancer (NSCLC) and Have Progressed on Prior EGFR Tyrosine Kinase Inhibitors (MK-2870-009) - Merck Sharp & Dohme LLCSee more
Kidney cancer
A Study of Subcutaneous Nivolumab Versus Intravenous Nivolumab in Participants With Previously Treated Clear Cell Renal Cell Carcinoma That is Advanced or Has Spread - CheckMate-67T - Bristol-Myers SquibbSee more
Skin cancer
A Clinical Study of V940 Plus Pembrolizumab in People With High-Risk Melanoma (V940-001) - V940-001 - Merck Sharp & Dohme LLCSee more
